Biomedical Engineering Reference
In-Depth Information
34. Hanahan D, Weinberg RA (2011) Hallmarks of cancer:
the next generation. Cell
144:646-674
35. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute
leukaemia in bcr/abl transgenic mice. Nature 344:251-253
36. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter
hypermethylation. N Eng J Med 349:2042-2054
37. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA
(2009) Potential etiologic and functional implications of genome-wide association loci for
human diseases and traits. Proc Natl Acad Sci U S A 106:9362-9367
38. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F,
Eerola I, Gerhard DS et al (2010) International network of cancer genome projects. Nature
464:993-998
39. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of optimal drug
combinations targeting cellular networks: integrating phospho-proteomics and computational
network analysis. Cancer Res 70:6704-6714
40. Ideker T (2004) Systems biology 101—what you need to know. Nat Biotechnol 22:473-475
41. Ideker T, Lauffenburger D (2003) Building with a scaffold: emerging strategies for high- to
low-level cellular modeling. Trends Biotechnol 21:255-262
42. Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM (2012) Merging systems biology with
pharmacodynamics. Sci Transl Med 4(126):126ps7
43. Jones HM, Gardner IB, Watson KJ (2009) Modelling and PBPK simulation in drug discov-
ery. AAPS J 11:155-166
44. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev
Genet 3:415-428
45. Kingsford C, Salzberg SL (2008) What are decision trees? Nat Biotechnol 26:1011-1013
46. Krogh A (2008) What are artificial neural networks? Nat Biotechnol 26:195-197
47. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ (2006) Drug development in oncology:
classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62:15-26
48. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ (2003) Tissue-
specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angio-
genesis and metastasis. Cancer Res 63:2971-2976
49. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and
transformation potency of bcr-abl oncogene products. Science 247:1079-1082
50. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-
oncogene addiction. Cell 136:823-837
51. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer
6:583-592
52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P,
Carlsson E, Ridderstrale M, Laurila E et al (2003) PGC-1alpha-responsive genes involved in
oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet
34:267-273
53. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street
SD (2011) Can the flow of medicines be improved? Fundamental pharmacokinetic and
pharmacological principles toward improving Phase II survival. Drug Discov Today
17(9-10):419-424
54. Nakajima M, Welch DR, Belloni PN, Nicolson GL (1987) Degradation of basement mem-
brane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell
clones of differing metastatic potentials. Cancer Res 47:4869-4876
55. Noble WS (2006) What is a support vector machine? Nat Biotechnol 24:1565-1567
56. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B,
Goldgraben MA, Caldwell ME, Allard D et al (2009) Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science
324:1457-1461
Search WWH ::
Custom Search